LentiviralMutagenesis_LS411N_TripleTherapy

NIAID Data Ecosystem2026-03-12 收录

癌细胞耐药性

BRAFV600E靶向治疗

数据链接：

https://www.ncbi.nlm.nih.gov/sra/ERP107259 数据链接链接失效反馈

官方服务：

资源简介：

Lentiviral mutagenesis is used to engender resistance to triple therapy of Trametinib, Dabrafenib and Cetuximab in the BRAF V600E colorectal cancer cell line LS411N.

创建时间：

2021-02-04

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma

癌细胞耐药性

索拉非尼药物敏感性

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma

integrated proteome resources50

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

癌细胞耐药性

细胞重编程

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

NIAID Data Ecosystem20

Barcode Sequencing Data of Dabrafenib Resistant HT-29 Cell Line

癌细胞耐药性

细胞谱系追踪

HT-29 cells were barcoded using the CloneTracker lentiviral barcode library and then dabrafenib resistant derivative of these cells were established. Five million barcoded HT-29 cells were seeded into

NIAID Data Ecosystem10

Genome-wide CRISPR inactivation based resistance screens using IMiDs in Primary Effusion Lymphoma (PEL) cells. Genome-wide CRISPR inactivation based resistance screens using IMiDs in Primary Effusion Lymphoma (PEL) cells

癌细胞耐药性

CRISPRi功能基因组学

We report the application of genome-wide CRISPR-Cas9 inactivation based screening technology to identify genes whose inactivation can confer resistance to the IMiD compounds Lenalidomide, Pomalidomide

NIAID Data Ecosystem50

STING agonism leads to durable clinical response in an anti-PD-L1 refractory patient: Tumor antigen-specific, single cell level biomarker analyses.. STING agonism leads to durable clinical response in an anti-PD-L1 refractory patient: Tumor antigen-specific, single cell level biomarker analyses.

癌细胞耐药性

单细胞生物标志物分析

Background: PD-1 pathway blockade has revolutionized cancer care, but many patients do not durably benefit from these therapies. Novel treatments to engage anti-tumor immunity in this setting are need

NIAID Data Ecosystem20

LentiviralMutagenesis_LS411N_TripleTherapy

资源简介：

相关数据集